172 related articles for article (PubMed ID: 26825962)
1. Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.
Ollech A; Stemmer SM; Merims S; Lotem M; Popovtzer A; Hendler D; Hodak E; Didkovsky E; Amitay-Laish I
Int J Dermatol; 2016 Apr; 55(4):473-8. PubMed ID: 26825962
[TBL] [Abstract][Full Text] [Related]
2. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
3. [Successful drug desensitization after vemurafenib-induced rash].
Klossowski N; Kislat A; Homey B; Gerber PA; Meller S
Hautarzt; 2015 Apr; 66(4):221-3. PubMed ID: 25698338
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
Pichard DC; Cardones AR; Chu EY; Dahut WL; Kong HH
JAMA Dermatol; 2016 Feb; 152(2):227-8. PubMed ID: 26422655
[No Abstract] [Full Text] [Related]
5. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
6. Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.
Tsuchiya N; Narita S; Inoue T; Hasunuma N; Numakura K; Horikawa Y; Satoh S; Notoya T; Fujishima N; Hatakeyama S; Ohyama C; Habuchi T
Anticancer Drugs; 2013 Mar; 24(3):310-4. PubMed ID: 23237922
[TBL] [Abstract][Full Text] [Related]
7. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
8. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Brade AM; Ng S; Brierley J; Kim J; Dinniwell R; Ringash J; Wong RR; Cho C; Knox J; Dawson LA
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):580-7. PubMed ID: 26867886
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
Zhou Q; Zhou CC; Chen GY; Cheng Y; Huang C; Zhang L; Xu CR; Li AW; Yan HH; Su J; Zhang XC; Yang JJ; Wu YL
Lung Cancer; 2014 Mar; 83(3):369-73. PubMed ID: 24440279
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
13. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
Jäger D; Ma JH; Mardiak J; Ye DW; Korbenfeld E; Zemanova M; Ahn H; Guo J; Leonhartsberger N; Stauch K; Böckenhoff A; Yu J; Escudier B
Clin Genitourin Cancer; 2015 Apr; 13(2):156-64.e1. PubMed ID: 25444666
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF
Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737
[TBL] [Abstract][Full Text] [Related]
16. [Acantholytic dermatosis in patients treated by vemurafenib: 2 cases].
Sabatier-Vincent M; Charles J; Pinel N; Challende I; Claeys A; Leccia MT
Ann Dermatol Venereol; 2014 Nov; 141(11):689-93. PubMed ID: 25442474
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
18. Radiation recall dermatitis induced by sorafenib : A case study and review of the literature.
Stieb S; Riesterer O; Brüssow C; Pestalozzi B; Guckenberger M; Weiler S
Strahlenther Onkol; 2016 May; 192(5):342-8. PubMed ID: 26907093
[TBL] [Abstract][Full Text] [Related]
19. Profile of vemurafenib-induced severe skin toxicities.
Peuvrel L; Quéreux G; Saint-Jean M; Brocard A; Nguyen JM; Khammari A; Knol AC; Varey E; Dréno B
J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):250-7. PubMed ID: 26524690
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib sensitivity skin reaction after ipilimumab.
Harding JJ; Pulitzer M; Chapman PB
N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
[No Abstract] [Full Text] [Related]
[Next] [New Search]
